# Omalizumab for Lupus

> **NCT01716312** · PHASE1 · COMPLETED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 17 (actual)

## Conditions studied

- Systemic Lupus Erthematosus
- Sjogren's Syndrome

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT01716312
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-08
- **Primary completion:** 2017-08-24
- **Final completion:** 2017-08-24
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01716312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01716312, "Omalizumab for Lupus". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT01716312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*